<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene L18F;D80A;D215G;L242del;R246I;K417N;E484K;N501Y;D614G;A701V literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.L18F;D80A;D215G;L242del;R246I;K417N;E484K;N501Y;D614G;A701V</span> literature reference collection</h1>
<div class="effect_section"><h2 id="convalescent_plasma_binding">Convalescent plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> In sera from six patients collected 1 to 12 weeks post-infection with B.1, antibody titer in a microneutralization assay was on average 8 for B.1.351 virus.<br/>Compare to much stronger neutralization titers for B.1.1.7 (256) and wild type (456.1) in the same sera.  (<a href="https://doi.org/10.1056/NEJMc2104036" class="lit_link">Luftig et al. (2021)</a>)</span></li>
<li class="lit_item"><span class="lit_summary"> Sera from individuals who have been infected with Delta does not have strong neutralising activity against Beta.<br/> (<a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf" class="lit_link">PHE UK (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="pharmaceutical_effectiveness">Pharmaceutical effectiveness</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> B.1.351 virus neutralization (as tested using biolayer interferometry) of both Lilly antibodies was severely impacted, with LY-CoV16 and LY-CoV555  (due to mutations at 416 and 484 respectively) shows almost complete loss of neutralization of B.1.351.<br/>There was also escape from neutralization of B.1.351 by REGN10933 and a modest reduction in neutralization of B.1.351 by AZD8895  (while AZD1061 and AZD7442 showed equal neutralization of all SARS-CoV-2 variants tested). The three Adagio antibodies neutralized B.1.351.<br/> (<a href="https://doi.org/10.1016/j.cell.2021.03.055" class="lit_link">Dejnirattisai et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccinee_plasma_binding">Vaccinee plasma binding</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> Sera from individuals who have been vaccinated and have had subsequent recent Delta infection have a high level of neutralising activity against Beta.<br/> (<a href="https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1009243/Technical_Briefing_20.pdf" class="lit_link">PHE UK (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
